JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

VOLUNTARY ANNOUNCEMENT
JACOBIO PRESENTED CLINICAL DATA OF KRAS G12C INHIBITOR GLECIRASIB IN PATIENTS WITH PANCREATIC CANCER AND OTHER SOLID TUMORS AT THE 2024 ASCO GI

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**" or "**Jacobio**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that, the Company announced its clinical data of Glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ("**2024 ASCO GI**").

As of December 6, 2023, the study of Glecirasib monotherapy enrolled 52 patients with pancreatic cancer and other solid tumors harboring KRAS G12C mutation in China, the United States, Europe, Israel and other regions, including 31 patients with pancreatic cancer, and 21 patients with other solid tumors (8 with biliary tract tumors, 3 with gastric cancer, 3 with small bowel cancer, 2 with appendix cancer and 5 with other solid tumors).

Among 50 patients with evaluable solid tumors, the confirmed objective response rate (cORR) was 48% (24/50) and the disease control rate (DCR) was 90% (45/50). For second-line and above KRAS G12C mutated pancreatic cancer patients, the cORR was 41.9% (13/31) and the DCR was 93.5% (29/31). The median progression-free survival (mPFS) was 5.6 months, and the median overall survival (mOS) was 10.7 months. In other solid tumor patients, the cORR was 57.9% (11/19), the DCR was 84.2% (16/19), the mPFS is 7.0 months, and the mOS has not yet matured. The above safety and efficacy data are better than the published data of similar studies.

Glecirasib has good tolerability and safety characteristics, the majority of treatment-related adverse events (TRAEs) are grades 1-2, and grade 3 or above TRAEs occurred in 25% of patients. No patient permanently withdraws from the study due to TRAEs.

The Company continues to explore the application of Glecirasib in pancreatic cancer and other solid tumors harboring KRAS G12C mutation. The registrational pivotal study for pancreatic cancer of Glecirasib was approved by Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China in July 2023, which became the first global pancreatic cancer KRAS G12C registrational clinical study. The study results will be used to submit New Drug Application (NDA) for pancreatic cancer.

Based on the clinical efficacy and safety data from ongoing clinical trials, Glecirasib was granted breakthrough therapy designation (BTD) by the CDE for the second-line and above treatment of the pancreatic cancer patients with a KRAS G12C mutation. Pancreatic cancer is a malignant tumor and there is a lack of effective treatment currently. The five-year overall survival rate is only 5%. The BTD will expedite the clinical development of Glecirasib and accelerate its early access to the patients.

For more information, please visit the official website of the ASCO GI: https://conferences.asco.org/gi/program.

About Glecirasib

Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. This includes a pivotal clinical trial in non-small cell lung cancer (NSCLC) in China; a monotherapy study for STK11 co-mutated NSCLC in the front-line setting, combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with Cetuximab in colorectal cancer, and a registrational pivotal clinical trial in pancreatic cancer.

About Jacobio

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Glecirasib (JAB-21822) will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. Please visit www.jacobiopharma.com for more information.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, January 21, 2024

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.